Sirius Medical has announced the second closing of its A-series round of financing. While the total amount of funding was left undisclosed, investors included BOM Brabant Ventures, Holland Capital, Curie Capital, together with the Sirius Medical team and angel investors. The Eindhoven-based medtech developer will use this injection of capital to help accelerate the expansion of its Pintuition system into new markets, with a focus on the US. Pintuition is a non-radioactive tumor localization solution, designed to assist and enable more precise and efficient tracking to aid in breast cancer and other cancer surgeries.
In addition to market acceleration, the funds will also be used to invest in technology innovation and product roadmap development. “I’m grateful for the enduring trust and commitment provided by our investors and the team at Sirius Medical,” says CEO Bram Schemers. “This financing round enables us to execute and accelerate our ambitious growth plans as well as further develop our innovation pipeline to deliver superior navigation technology to physicians and patients worldwide.”